Latest news with #XcellBiosciences
Yahoo
03-07-2025
- Business
- Yahoo
Thermo Fisher and Xcell Biosciences Partner to Advance TIL and Treg Cell Therapies
Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc. (NYSE:TMO) partnered with Xcell Biosciences, an instrumentation firm specializing in cell and gene therapy applications, to advance research on tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs). While an extensive amount of progress has been achieved on the subject of cell therapy using Chimeric Antigen Receptor T (CAR T) cells, the primary objective of this collaboration is to develop Treg and TIL cell therapies that are specifically designed to fight solid tumors and autoimmune diseases. The collaboration also aims to increase scalability and consistency in cell therapy production while streamlining operations to assist patients in having more access to these vital treatments. Speaking on this partnership, Thermo Fisher Scientific Inc. (NYSE:TMO)'s senior director of research and development, Andy Campbell, stated the following: 'We are confident that this collaboration will significantly shorten and enhance the manufacturing workflow for cell therapies in this space, ultimately helping our customers make the world a healthier place.' Thermo Fisher Scientific Inc. (NYSE:TMO) serves a variety of global markets with a broad range of products and services related to analytical instruments, specialty diagnostics, life sciences solutions, and laboratory supplies. The company also offers an array of genome editing solutions, such as guide RNA (gRNA), mRNA, plasmids, and CRISPR proteins. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24-06-2025
- Business
- Business Wire
Xcell Biosciences Announces Joint Research Collaboration with Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies
SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused on cell and gene therapy applications, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs). While significant progress has been made in the cell therapy space leveraging Chimeric Antigen Receptor T (CAR T) cells, this collaboration aims to advance Treg and TIL cell therapies that specialize in combating autoimmune and solid tumor diseases. With solid tumors representing approximately 90 percent of adult cancers and instances of autoimmune diseases on the rise worldwide, this collaboration looks to target a crucial area for improving global health. Leveraging the strengths of both companies, the joint research will focus on developing new methodologies to enhance the efficacy of Tregs and TILs in therapeutic applications. The collaboration also seeks to streamline workflows while improving scalability and reproducibility in cell therapy manufacturing to help make these critical treatments more accessible to patients. 'We are thrilled to collaborate with Thermo Fisher Scientific on groundbreaking research opportunities. By leveraging our AVATAR™ cell therapy manufacturing platform, we aim to push the boundaries of what is possible in cell and gene therapy. This partnership will enable us to develop more effective treatments for patients in need,' said Shannon Eaker, chief technology officer at Xcell Biosciences. Thermo Fisher has supported the majority of the approved cell therapies in the market by providing critical tools and materials as well as helping to automate and accelerate manufacturing. 'Xcellbio's interest in utilizing our Gibco™ CTS™ Detachable Dynabeads™ platform within Thermo Fisher Scientific's modular, closed and automated cell therapy manufacturing workflow is a testament to the strength of our technologies,' said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. 'In combination with our full portfolio, including the Gibco™ CTS™ DynaCellect™ Magnetic Separation System and the Gibco™ CTS™ Rotea Counterflow Centrifugation System, we are confident that this collaboration will significantly shorten and enhance the manufacturing workflow for cell therapies in this space, ultimately helping our customers make the world a healthier place.' To learn more about Xcellbio and its Avatar platform, visit To learn more about Thermo Fisher and its Cell Therapy Systems, visit About Xcell Biosciences Xcellbio is driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company's commercial instruments and software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cGMP cell therapy manufacturing platform. Based in San Francisco and Melbourne, Australia, Xcellbio can also be found online at
